Post-surgical complication contribute significantly to hospital profit margins, says a new study published in the journal JAMA…
Tag Archives: JAMA
Study: Many Invasive Medical Procedures are the Result of Uncertainty, Not Evidence
Few of us are comfortable with uncertainty in any form, least of all when the status of our health is branded with the scarlet question mark. A new study set to publish this week in the journal JAMA suggests that this uncertainty is fueling a psychological dynamic that’s leading to more and more invasive procedures–whether or not we need them.
Alzheimer's Gene Doubles Risk In African-Americans
A variation in the gene ABCA7 causes the risk of late-onset Alzheimer’s disease to double in African-Americans, according to a new study in JAMA…
Mortality Rates At Rural Hospital Unusually High
Death rates for medicare beneficiaries being treated at critical access hospitals in rural areas increased from 2002 to 2010, while rates in other hospitals fell, according to new research published in JAMA. The analysis, led by Karen E. Joynt, M.D., M.P.H… …read more
Source: FULL ARTICLE at Medical News Today
Duloxetine Reduces Chemo-Induced Neuropathy
Duloxetine, an antidepressant, was shown to reduce painful peripheral neuropathy caused by neurotoxic chemotherapy in a study published in JAMA. Researchers from the University of Michigan School of Nursing added that duloxetine benefited the majority of patients in their study… …read more
Source: FULL ARTICLE at Medical News Today
A Guide To The Raging Debate Over The NIH's TACT Chelation Trial
By Larry Husten, Contributor The publication in JAMA of the NIH’s Trial To Assess Chelation Therapy (TACT) trial has provoked a fascinating debate in the blogosphere. The vast majority of responsible physicians and healthcare professionals have little interest in chelation therapy per se, but the TACT trial has raised many important questions about the nature of medical evidence. Here’s a brief guide with links to some of the more interesting discussions (let me know if you are aware of other worthwhile discussions): …read more
Source: FULL ARTICLE at Forbes Latest
The "World's Greatest Retirement Portfolio" Continues to Outperform
By Brian Stoffel, The Motley Fool
Filed under: Investing
It’s been almost 23 months since I introduced the World’s Greatest Retirement Portfolio to Foolish readers. This was, has been, and will continue to be my way of helping the world to invest better. Putting my money where my mouth is, I pledged to put at least $4,000 behind each stock and attempt to hold each one for at least three years — though I’ve already broken that promise.
Since I began, the market has returned 24.1%, which is pretty darn good by historical measures. Though this portfolio has been outperforming the market by double digits for well over a year now, it is currently ahead by just 3.3 percentage points.
Read below to see why the margin between the two is narrowing, and at the end, I’ll offer up access to a special premium report on one of these 10 companies.
|
Company |
Publication Date |
Change |
Vs. S&P 500 |
|---|---|---|---|
|
|
64.4% |
38 |
|
|
PriceSmart |
56.7% |
31 |
|
|
Baidu |
(20.8%) |
(44) |
|
|
Intuitive Surgical |
22.4% |
1 |
|
|
National Oilwell Varco |
(11.8%) |
(37) |
|
|
Coca-Cola |
28.1% |
3 |
|
|
Whole Foods |
40.3% |
19 |
|
|
Amazon.com |
26.1% |
3 |
|
|
Apple |
33.8% |
11 |
|
|
Johnson & Johnson |
34.7% |
8 |
|
Source: Fool.com. All numbers accurate as of market close March 31, 2013. *Returns are for position in ATVI held from July 15, 2011, to Sept. 9, 2012, and transferred over to BIDU on Sept. 15, 2012.
One company that can’t catch a break
More or less, the companies in this portfolio didn’t perform terribly during the month of March, they just weren’t able to keep pace with the S&P 500, which climbed over 3% during the month. That wasn’t the case, however, for Intuitive Surgical , maker of the da Vinci surgical robot.
I’ve covered the stock’s dive already, but there are three simple events that caused the stock to drop. First, the Journal of the American Medical Association questioned the need for robotic hysterectomies. Second, the FDA announced it was investigating a rise in the company’s incidents reports. Finally, the president of the American Congress of Obstetricians and Gynecologists publicly echoed the concerns raised in the JAMA article.
Three companies having a good month
Even though the portfolio as a whole isn’t leading the market by quite as much, three stocks had a relatively good March.
Shares of Latin American club wholesaler PriceSmart were up 5%. This came on the heels of the announcement that the company’s net sales increased 7.8% during the month of February, which included an impressive 8.9% increase in same-store sales. PriceSmart also announced it has acquired land in Tegucigalpa, Honduras, to open up its third store in the country.
The total return from my investments in Coca-Cola and Johnson & Johnson also increased markedly during March. Part of this was due to the fact that Coke issued its quarterly dividend …read more
Source: FULL ARTICLE at DailyFinance
Physical And Mental Activity Greatly Improve Cognitive Function Among Older Adults
A new study published in JAMA revealed that inactive, older adults, suffering from cognitive complaints, who completed 12 weeks of physical plus mental activity, experienced significant improvement in their cognitive function. However, there was little difference between the control and intervention group… …read more
Source: FULL ARTICLE at Medical News Today
Oral Drops Effective At Treating Allergies
Oral allergy drops have proved to be an effective alternative to using weekly injections or medications to treat allergies, according to new research at Johns Hopkins University. The liquid drops include small amounts of purified pollen, mold, dust mites and grasses. Researchers at Johns Hopkins published their report in the latest edition of the JAMA… …read more
Source: FULL ARTICLE at Medical News Today
Controversial NIH Chelation Trial Published In JAMA
By Larry Husten Final results of the troubled NIH-sponsored TACT trial testing chelation therapy for coronary disease have now been published in JAMA. Last November, when the preliminary results were presented at the American Heart Association meeting, the positive finding in favor of chelation therapy surprised many observers, though the investigators and senior AHA representatives expressed considerable caution about the proper interpretation of the results. Full publication of the main results should now allow for a more thorough consideration of the trial. …read more
Source: FULL ARTICLE at Forbes Technology
3 Stocks Trying to Hold the Dow Back
By Matt Thalman, The Motley Fool
Filed under: Investing
Once again, the Dow Jones Industrial Average is pushing higher today. As of 12:55 p.m. EDT, the index has added 64 points, or 0.44%. It’s poised not only to set a new record closing high, but also to stretch its winning streak to 10 days.
The markets in general are moving higher today. The S&P 500 has gained another 0.41%, leaving it just four points away from its all-time high of 1,565, while the NASDAQ is higher by 0.33%. But even as the markets move closer to setting new highs, a few losers are attempting to hold the indexes back.
Today’s Dow downers
Shares of Merck have fallen 1% today after new reports indicated that the U.S. Food and Drug Administration is reviewing documents connecting Merck’s Januvia drug to serious health issues. The study from JAMA Internal Medicine claims to have found a link between certain diabetes medications, including Januvia, and increased pancreatic problems. The FDA‘s looking into how JAMA collected the data and what led the study’s authors to their conclusion.
At this time, the FDA has not given any official statement on whether Januvia is harmful or not. But if officials find the drug does cause further harm, it may be taken off the market. At the very least, it could come with much more severe side-effect warnings, which would likely lead doctors to prescribe it less frequently.
In the world of retail, shares of Wal-Mart are down 0.4%. The company relies on shoppers receiving and spending their tax refunds during this time of year, and so far 2013 has not been good for refunds.
First, the IRS pushed the earliest possible filing day back by more than a week because of tax code changes resulting from the fiscal-cliff compromise. In February, those claiming earned-income tax credits were hit by refund delays. Now the IRS is claiming that refunds for more than 6000,000 taxpayers who claim an education credit will be delayed for up to six weeks.
On Tuesday a Wal-Mart executive said customers had cashed in refund checks worth $2.7 billion. But at this time last year, the company had processed about $4 billion worth of refund checks, much of which was later spent in its big-box stores.
Lastly, Caterpillar is trading lower by 0.6% following reports that company employees in Europe are protesting against recent moves to cut its European workforce. The EU‘s manufacturing industry has struggled since the recession hit. Combine industry layoffs and wage cutbacks with the austerity programs many EU countries have been forced into, and it’s easy to see how further job cuts could set off protests and, possibly, strikes. If the company is hit with a strike, both its short-term and long-term costs will likely climb, lowering its profits.
Caterpillar is the market share leader in an industry in which size matters, and its quality products, extensive service network, and unparalleled brand strength combine to give it solid competitive advantages. …read more
Source: FULL ARTICLE at DailyFinance
Breastfeeding Does Not Lower Risk Of Child Obesity
Breastfeeding does not appear to lower a child’s risk of being overweight or obese. The finding came from a new study led by researchers at the University of Bristol, England, and was published in JAMA… …read more
Source: FULL ARTICLE at Medical News Today
Hospitals Seeing Rapidly Growing Numbers Of Adults With Congenital Heart Disease
By Larry Husten Hospitals are treating increasing numbers of adults with congenital heart disease, thanks to tremendous progress in treatment for this condition in recent decades. A clear picture of this dramatic change emerges in a new study, presented at the ACC in San Francisco and published simultaneously in JAMA. …read more
Source: FULL ARTICLE at Forbes Health
Study: Missed Diagnoses in the Doctor's Office are Leading to Thousands of Deaths
A new study published in JAMA indicates that primary care doctors are increasingly missing diagnoses at the office, resulting in thousands of deaths and disabilities per year. …read more
Source: FULL ARTICLE at Forbes Latest
Robotically-Assisted Hysterectomy Usage Significantly Increased, Little Benefit
The use of robotically-assisted hysterectomy has significantly increased, however, it offers few benefits in the short-term and costs substantially more compared to laparoscopic hysterectomy. The finding came from new research which analyzed hysterectomies for benign gynecologic disorders between 2007 and 2010 and was published in JAMA… …read more
Source: FULL ARTICLE at Medical News Today
Folic Acid Supplementation Before And During Pregnancy Lowers Autism Risk In Offspring
Women who take folic acid supplements four weeks before becoming pregnant and also during the first weeks of pregnancy have a lower risk of giving birth to children who eventually become diagnosed with an autism spectrum disorder (ADS), Norwegian researchers reported in JAMA… …read more
Source: FULL ARTICLE at Medical News Today
Is Increase In Hospice And ICU Usage What Elderly Patients Want?
There has been an increase in hospice usage and ICU utilization over the last ten years among elderly patients, researchers from Brown University reported in JAMA. The authors added that with more late health care transitions, repeat hospitalizations, does such aggressive care really represent what patients and their loved ones really want? Probably not… …read more
Source: FULL ARTICLE at Medical News Today
Ramipril Improves Walking For People With PAD
Pain-free walking as well as length of walk both improved greatly in patients with claudication following treatment with the ACE blocker ramipril. The new study, published in JAMA, revealed pain-free walking rose by 60 percent on average and maximum walking time doubled following six months of treatment with the ACE inhibitor… …read more
Source: FULL ARTICLE at Medical News Today
ACE Inhibitor Improves Walking In People with Peripheral Artery Disease
By Larry Husten, Contributor Giving an ACE inhibitor to people with peripheral artery disease (PAD) and intermittent claudication reduces pain and increases walking time, according to a new study published in JAMA. Currently the pharmacologic options for this patient population are few and have limited efficacy.
Source: FULL ARTICLE at Forbes Latest
High Probability of Readmission After Hospitalization
An estimated 2 in every 10 people who are hospitalized have to receive acute care 30 days following discharge, with close to 40 percent of such cases resulting in emergency department visits. This finding comes from a recent study published in the latest issue of JAMA…
Source: FULL ARTICLE at Medical News Today